Research results supporting the cognitive improvement effects of the brain function enhancer choline alfoscerate have been published in an SCIE-level journal, while Daewoong Bio's Gliatamine recorded its highest-ever performance last year.
Daewoong Bio announced on the 10th that its brain function enhancer containing choline alfoscerate, 'Gliatamine,' achieved sales of 129.3 billion KRW last year. This represents approximately 22% growth compared to 106.1 billion KRW in 2022, maintaining its position as the top-selling drug in the same category.
The main ingredient of Gliatamine, choline alfoscerate, promotes the synthesis of acetylcholine, a neurotransmitter that plays a central role in cognitive functions such as memory and learning. Based on its long-proven efficacy through prescriptions and minimal side effects, it is widely used for diseases related to cognitive decline.
In particular, Gliatamine is characterized by offering various formulations such as capsules, injections, and syrups among drugs in the same category, providing patients with convenience in administration and a broad range of treatment options.
Last November, a study revealing the cognitive improvement effects of choline alfoscerate, the main ingredient of Gliatamine, was published in an SCIE-level journal, drawing attention. The research team from Bundang Seoul National University Hospital concluded that choline alfoscerate could be considered a treatment option for preserving cognitive function and physical health.
In this study, patients who took choline alfoscerate for six months showed an increase in Mini Mental State Examination (MMSE) scores from 26.2 to 26.9, while the placebo group’s scores decreased from 26.6 to 25.9. The average difference between the two groups was 1.4 points, which increased to 1.7 points after 12 months, achieving statistical significance.
Additionally, meaningful improvements were observed in the 'Quality of Life Index' survey, which measures physical health across four categories (general health, physical function, physical role, and pain), indicating that choline alfoscerate contributes not only to neuroprotection but also to enhancing physical abilities.
Choline alfoscerate currently holds indications for secondary symptoms caused by cerebrovascular defects, degenerative or atrophic brain syndrome, memory impairment and confusion, disorientation due to decreased motivation and spontaneity, and reduced concentration. Since receiving product approval and insurance reimbursement in Korea in 1995, it has been actively prescribed in medical settings for over 30 years. Furthermore, it is approved as a prescription drug in 10 countries including Italy, Russia, and Poland, and is widely used worldwide.
A Daewoong Bio official stated, "Gliatamine has been continuously prescribed and loved by many medical professionals and patients due to its proven outstanding effects in clinical practice," adding, "In a situation where there are no clear alternatives for patients with dementia and mild cognitive impairment, we will do our best to improve patients’ quality of life."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
